Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 12.86B | 12.86B | 11.53B | 10.43B | 11.40B | 9.00B |
Gross Profit | 7.77B | 8.76B | 7.10B | 6.27B | 7.56B | 6.29B |
EBITDA | 3.11B | 3.11B | 2.46B | 1.13B | 2.27B | 2.73B |
Net Income | 782.93M | 782.93M | 318.74M | -325.33M | 606.62M | 1.48B |
Balance Sheet | ||||||
Total Assets | 33.11B | 33.11B | 30.93B | 29.04B | 28.75B | 26.32B |
Cash, Cash Equivalents and Short-Term Investments | 585.61M | 585.61M | 302.26M | 221.92M | 338.29M | 1.23B |
Total Debt | 5.88B | 5.88B | 9.37B | 7.98B | 6.83B | 8.46B |
Total Liabilities | 9.47B | 9.47B | 12.93B | 11.30B | 10.64B | 11.65B |
Stockholders Equity | 23.72B | 23.72B | 18.09B | 17.83B | 18.22B | 14.79B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -1.11B | -492.22M | -467.44M | -2.27B | -3.07B |
Operating Cash Flow | 0.00 | 1.32B | 1.35B | 1.80B | 1.05B | 469.28M |
Investing Cash Flow | 0.00 | -1.99B | -1.67B | -2.33B | -2.85B | -4.04B |
Financing Cash Flow | 0.00 | 626.54M | 1.39B | 457.98M | 828.58M | 4.36B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | 1.05T | 18.39 | 16.23% | 0.64% | 15.86% | 2.02% | |
72 Outperform | 648.75B | 28.40 | 18.07% | 0.83% | 4.49% | 11.22% | |
66 Neutral | 452.43B | 47.61 | 47.54% | 2.02% | 6.65% | 48.47% | |
62 Neutral | 109.39B | 30.18 | 48.02% | 2.47% | -23.93% | -31.53% | |
55 Neutral | ₹75.35B | 67.84 | ― | 0.13% | 11.13% | 127.34% | |
54 Neutral | 556.02B | 73.77 | 11.83% | 0.13% | 10.99% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shilpa Medicare Limited has announced the dispatch of the notice for its 38th Annual General Meeting, as published in Business Line and Suddimoola newspapers. This announcement is part of the company’s compliance with regulatory requirements, reflecting its commitment to transparency and stakeholder engagement.
Shilpa Medicare Limited, through its wholly owned subsidiary Koanna International FZ LLC, has entered into a joint venture with Pharma Pharmaceutical Industries & Biological Products (PPI) to establish a new pharmaceutical manufacturing facility in Saudi Arabia. This strategic move is expected to enhance Shilpa’s global footprint and strengthen its presence in the MENA region, allowing the company to supply and locally manufacture pharmaceutical formulations, thereby consolidating its market position.
Shilpa Medicare Limited has released the transcript of its Q1 FY26 earnings conference call, which took place on August 13, 2025. This release provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
Shilpa Medicare Limited has announced the approval of its Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg by the Central Drugs Standard Control Organization (CDSCO) for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in India. This approval marks a significant milestone as it positions Shilpa Medicare as the first company globally to launch this novel product for NAFLD, addressing a major unmet medical need. The introduction of NorUDCA, which has demonstrated superior efficacy over placebo, underscores Shilpa’s commitment to innovation and accessible healthcare, potentially impacting millions affected by liver disease in India and beyond.